Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

about

Selective estrogen receptor modulator (SERM) lasofoxifene forms reactive quinones similar to estradiol Current and emerging therapies for the treatment of osteoporosis Raloxifene hydrochloride for breast cancer risk reduction in postmenopausal women.

P2860

Q36098828-C76DD699-30E1-494C-9018-8D7771A88E27 Q36890431-307F064B-BF17-47E8-A4DF-FAA51DB6BC48 Q38825454-E95226C3-01AA-4582-97C4-54ABB01B071F

P2860

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

Item

http://www.wikidata.org/entity/Q37412956

description

2009 nî lūn-bûn

@nan

2009年の論文

@ja

2009年学术文章

@wuu

2009年学术文章

@zh-cn

2009年学术文章

@zh-hans

2009年学术文章

@zh-my

2009年学术文章

@zh-sg

2009年學術文章

@yue

2009年學術文章

@zh

2009年學術文章

@zh-hant

name

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

@en

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

@nl

type

Item

label

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

@en

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

@nl

prefLabel

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

@en

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

@nl

P1476

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

@en

P2093

E Michael Lewiecki

http://www.w3.org/2001/XMLSchema#string

P2860

Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial

Assessment of fracture risk and its application to screening for postmenopausal osteoporosis. Report of a WHO Study Group

The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis

Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial

Effects of conjugated equine estrogen in postmenopausal women with hysterectomy: the Women's Health Initiative randomized controlled trial

Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis

Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group.

Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study.

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Raloxifene hydrochloride.

P304

817-827

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S5645

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2009-11-02T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

19898646

http://www.w3.org/2001/XMLSchema#string

P921

osteoporosis

P932

2773750

http://www.w3.org/2001/XMLSchema#string

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

about

P2860

P2860

Lasofoxifene for the prevention and treatment of postmenopausal osteoporosis.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P478

P577

P698

P921

P932